At the end of each year, business development and marketing specialists across the globe are busy identifying strategies and components to plan an annual marketing budget. Accordingly, this time around, given the season, we asked Law Firm Marketing experts across the CEE region a question: Which metrics do you look at when planning your marketing budget?

DLA Piper has announced that Oppenheim Partners Gabor Fejes and Zoltan Marosi are set to join the firm as a Partner and Local Partner, respectively, early in 2022.

On 21 September 2021, the Commission launched a public consultation on the revision of the general pharmaceutical legislation. The public consultation ends on 21 December 2021. Any interested party may submit comments and observations. The consultation concerns certain key topics such as access and affordability, solutions to address unmet medical needs, incentives for innovation, medicine shortages, environmental challenges and sustainability. The amendments of the general pharmaceuticals legislation may be however much wider in scope, in line with the strategic areas identified in the Pharmaceutical Strategy for Europe, as part of which the public consultation is organized. Following the consultation process, the Commission will adopt a final legislative proposal, which is expected to be published by the fourth quarter of 2022.

The DLA Piper report “The COVID-19 pandemic and the pharmaceutical and medical sector in Poland” is based on the feedback from a survey conducted among DLA Piper’s clients and business contacts from the pharmaceutical and medical sector, including producers of medicines, food supplements and medical devices, as well as healthcare service providers. It is the first report that brings together the views of key players in the pharmaceutical and medical industries, describing how they see the current state of affairs on the Polish market and possible future trends, along with their recommendations as to what actions they would like to see taken in the sector. The key findings are summarised in our four briefings, the last part of which discusses other consequences of the pandemic not yet mentioned as well as sector barriers and suggested state actions.

The DLA Piper report “The COVID-19 pandemic and the pharmaceutical and medical sector in Poland” is based on the feedback from a survey conducted among DLA Piper’s clients and business contacts from the pharmaceutical and medical sector, including producers of medicines, food supplements and medical devices, as well as healthcare service providers. It is the first report that brings together the views of key players in the pharmaceutical and medical industries, describing how they see the current state of affairs on the Polish market and possible future trends, along with their recommendations as to what actions they would like to see taken in the sector. The key findings are summarised in our four briefings, the third of which focuses on patients’ rights, the product market and an evaluation of the state’s actions during the pandemic.

The DLA Piper report “The COVID-19 pandemic and the pharmaceutical and medical sector in Poland” is based on the feedback from a survey conducted among DLA Piper’s clients and business contacts from the pharmaceutical and medical sector, including producers of medicines, food supplements and medical devices, as well as healthcare service providers. It is the first report that brings together the views of key players in the pharmaceutical and medical industries, describing how they see the current state of affairs on the Polish market and possible future trends, along with their recommendations as to what actions they would like to see taken in the sector. The key findings are summarised in our four briefings, the second of which concentrates on the impact of the pandemic on reimbursement and on the organisation of the healthcare system.

The DLA Piper report “The COVID-19 pandemic and the pharmaceutical and medical sector in Poland” is based on the feedback from a survey conducted among DLA Piper’s clients and business contacts from the pharmaceutical and medical sector, including producers of medicines, food supplements and medical devices, as well as healthcare service providers. It is the first report that brings together the views of key players in the pharmaceutical and medical industries, describing how they see the current state of affairs on the Polish market and possible future trends, along with their recommendations as to what actions they would like to see taken in the sector. The key findings are summarised in our four briefings, the first of which focuses on the overall impact of the pandemic as well as relations with healthcare professionals and clinical trials.

DLA Piper’s Andras Nemescsoi and Gabor Molnar Talk About The Deal of the Year in Hungary.

Once the amendment to the Czech Consumer Protection Act becomes effective, consumer protection rules shall have to start being reflected in the digital world. If the amending legislation is passed in its current draft form, consumer protection rules shall also apply to the offering and provision of digital content and services, even if the consumers "pays" for them with their personal data. Violations of the new obligations shall be punishable by a fine of up to CZK 50.000.000 or 4% of the trader’s annual turnover. The amendment implements the requirements set by EU law.

In July, new Arbitration and Mediation Rules of the Vienna International Arbitration Centre ("VIAC" and "VIAC Rules") entered into force. The revised VIAC Rules will apply to arbitrations commenced after 30 June 2021.

Recently, the President of the Office of Competition and Consumer Protection (Polish name: Urząd Ochrony Konkurencji i Konsumentów “UOKiK”) announced the initiation of antimonopoly proceedings in connection with the suspected coordination of actions by the Polish Basketball League and its member clubs against their players. The aim of the collusion was, among other things, to agree the terms of termination of players' contracts and to withhold payment of their salaries.

DLA Piper Warsaw Head of Corporate/M&A Marta Frackowiak has been elected as representative of the EMEA region the firm’s International Board - the body that acts as the firm's supervisory board.

Every spring DLA Piper publishes its annual M&A intelligence report. This past spring, we could only speculate on the effects of the pandemic as COVID-19 had just hit Europe. Informed by our experience of the past few months, we have recently published our updated M&A Global Report. Below we highlight a couple of trends that are impacting CEE. 

After many years of liberalization and globalization, recent years have shown a reversal of the European Union’s approach concerning foreign direct investment from third countries. As in much of the world, the EU has taken a more restrictive view than in the past, and this view is reflected on the legislative level with the FDI Screening Regulation.

An interview with Julien Hansen of DLA Piper Moscow.

The legal markets of Central and Eastern Europe are served by a growing cadre of strong domestic firms, an established collective of widely-recognized and genuinely impressive regional firms … and, of course, many of the largest and best international firms in the world.

Something Needs to Be Done

The Spring of 2020 was about to blossom when the world got trapped in a global shutdown as a result of the COVID-19 pandemic. The private sector tried to adapt by activating continuity plans. Working from home and interacting online with colleagues and customers has become the new paradigm for service businesses. In addition to a wide range of social distancing restrictions designed to contain the virus (including closing down or significantly limiting public access to many commercial, government, and leisure facilities), Romanian authorities have instituted various specific temporary relief measures, such as unemployment benefits; moratoria on consumer and corporate debt, business rent, and utilities expenses; state aid schemes representing loan and guarantee facilities for small and medium-size enterprises (SMEs); guarantees for mortgage loans; filing deferral for tax returns and rescheduling of income and property tax; and waivers of mandatory insolvency filing  and extension of certain stages in pending insolvency cases.